DxS Signs US Companion Dx Deal with Amgen for K-RAS Test | GenomeWeb
NEW YORK (GenomeWeb News) – Pharmagogenomics firm DxS said today that it has signed an agreement with Amgen to market its K-RAS assay as a companion diagnostic for Amgen’s Vectibix (panitumumab) colorectal cancer therapy in the US.
 
Under the terms of the agreement, DxS’ TheraScreen K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the US Food and Drug Administration, DxS said. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.